UBS analyst Danielle Antalffy lowered the firm’s price target on Baxter (BAX) to $21 from $24 and keeps a Neutral rating on the shares. Baxter delivered a Q3 sales miss vs. consensus across all businesses excluding Advanced Surgery and also cut its quarterly dividend, the analyst tells investors in a research note. Consensus numbers for 2026 will likely have to come down, and sales growth in 2026 might be tough to come by, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: